BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(42): 5286-5296 [PMID: 21072891 DOI: 10.3748/wjg.v16.i42.5286] [Cited by in CrossRef: 230] [Cited by in F6Publishing: 210] [Article Influence: 19.2] [Reference Citation Analysis]
Number Citing Articles
1 Capitan V, Petit J, Aho S, Lefevre P, Favelier S, Loffroy R, Hillon P, Krausé D, Cercueil J, Guiu B. Macroscopic heterogeneity of liver fat: an MR-based study in type-2 diabetic patients. Eur Radiol 2012;22:2161-8. [DOI: 10.1007/s00330-012-2468-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
2 El-ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. European Journal of Gastroenterology & Hepatology 2019;31:859-64. [DOI: 10.1097/meg.0000000000001354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Annals of Hepatology 2012;11:172-8. [DOI: 10.1016/s1665-2681(19)31021-x] [Cited by in Crossref: 34] [Article Influence: 3.4] [Reference Citation Analysis]
4 Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012;59:442-9. [DOI: 10.1016/j.cyto.2012.05.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
5 Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, Zarrinpar A, Petrowsky H, Farmer D, Yersiz H, Xia V, Hiatt JR, Busuttil RW. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg. 2012;256:624-633. [PMID: 22964732 DOI: 10.1097/sla.0b013e31826b4b7e] [Cited by in Crossref: 167] [Cited by in F6Publishing: 73] [Article Influence: 16.7] [Reference Citation Analysis]
6 Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 2013;48:1051-1060. [PMID: 23184095 DOI: 10.1007/s00535-012-0704-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
7 Hearn C, Ellington BJ, Jones R. The Role of the Nurse Practitioner in the Management of Nonalcoholic Fatty Liver Disease. Gastroenterol Nurs 2018;41:424-6. [PMID: 30272604 DOI: 10.1097/SGA.0000000000000394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
9 Greaves P. Liver and Pancreas. Histopathology of Preclinical Toxicity Studies. Elsevier; 2012. pp. 433-535. [DOI: 10.1016/b978-0-444-53856-7.00009-9] [Cited by in Crossref: 8] [Article Influence: 0.8] [Reference Citation Analysis]
10 Yilmaz Y, Colak Y, Kurt R, Senates E, Eren F. Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. Tumori 2013;99:10-6. [DOI: 10.1177/030089161309900102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Orasan OH, Iancu M, Sava M, Saplontai-Pop A, Cozma A, Sarlea ST, Lungoci C, Ungureanu MI, Negrean V, Sampelean D, Dumitrascu DL. Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Eur J Clin Invest 2015;45:1243-51. [PMID: 26426402 DOI: 10.1111/eci.12543] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
12 Bastati N, Feier D, Wibmer A, Traussnigg S, Balassy C, Tamandl D, Einspieler H, Wrba F, Trauner M, Herold C, Ba-Ssalamah A. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology. 2014;271:739-747. [PMID: 24576046 DOI: 10.1148/radiol.14131890] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
13 Suzuki A, Kakisaka K, Suzuki Y, Wang T, Takikawa Y. c-Jun N-terminal kinase-mediated Rubicon expression enhances hepatocyte lipoapoptosis and promotes hepatocyte ballooning. World J Gastroenterol 2016; 22(28): 6509-6519 [PMID: 27605885 DOI: 10.3748/wjg.v22.i28.6509] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
14 Jain AK, Sharma A, Arora S, Blomenkamp K, Jun IC, Luong R, Westrich DJ, Mittal A, Buchanan PM, Guzman MA, Long J, Neuschwander-Tetri BA, Teckman J. Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition. JPEN J Parenter Enteral Nutr 2017;41:198-207. [PMID: 27503935 DOI: 10.1177/0148607116661838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
15 Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, Ikhwan MA, Bassirian S, Cepin S, Gonzalez MP, Mendler M, Kono Y, Vodkin I, Mekeel K, Haldorson J, Hemming A, Andrews B, Salotti J, Richards L, Brenner DA, Sirlin CB, Loomba R; Familial NAFLD Cirrhosis Research Consortium. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127:2697-704. [PMID: 28628033 DOI: 10.1172/JCI93465] [Cited by in Crossref: 72] [Cited by in F6Publishing: 36] [Article Influence: 14.4] [Reference Citation Analysis]
16 Karjoo S. Is There an Association of Vascular Disease and Atherosclerosis in Children and Adolescents With Obesity and Non-alcoholic Fatty Liver Disease? Front Pediatr 2018;6:345. [PMID: 30505829 DOI: 10.3389/fped.2018.00345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kumar JA, Teckman JH. Controversies in the Mechanism of Total Parenteral Nutrition Induced Pathology. Children (Basel) 2015;2:358-70. [PMID: 27417369 DOI: 10.3390/children2030358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
18 Kumar A, Shalimar, Walia GK, Gupta V, Sachdeva MP. Genetics of nonalcoholic fatty liver disease in Asian populations. J Genet 2019;98. [DOI: 10.1007/s12041-019-1071-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
19 Bunnoy A, Saenphet K, Lumyong S, Saenphet S, Chomdej S. Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats. BMC Complement Altern Med 2015;15:88. [PMID: 25880551 DOI: 10.1186/s12906-015-0624-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
20 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
21 Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58:1497-1507. [PMID: 23299992 DOI: 10.1002/hep.26226] [Cited by in Crossref: 288] [Cited by in F6Publishing: 275] [Article Influence: 32.0] [Reference Citation Analysis]
22 Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl. 2019;25:56-67. [PMID: 30609189 DOI: 10.1002/lt.25338] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
23 Li H, Yoo W, Park HM, Lim SY, Shin DH, Kim S, Park HY, Jeong TS. Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model. Int J Mol Sci 2019;20:E2325. [PMID: 31083413 DOI: 10.3390/ijms20092325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong JW, Khan NA, Abu Bakar MR, Ng BH, Yuen KH. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J. 2013;12:166. [PMID: 24373555 DOI: 10.1186/1475-2891-12-166] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
25 Knittelfelder O, Traikov S, Vvedenskaya O, Schuhmann A, Segeletz S, Shevchenko A, Shevchenko A. Shotgun Lipidomics Combined with Laser Capture Microdissection: A Tool To Analyze Histological Zones in Cryosections of Tissues. Anal Chem 2018;90:9868-78. [PMID: 30004672 DOI: 10.1021/acs.analchem.8b02004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
26 Swain M, Nath P, Parida PK, Narayan J, Padhi PK, Pati GK, Singh A, Misra B, Misra D, Kar SK, Panigrahi MK, Meher C, Agrawal O, Rout N, Pattnaik K, Bhuyan P, Mishra PK, Singh SP. Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation. Indian J Clin Biochem 2017;32:306-14. [PMID: 28811690 DOI: 10.1007/s12291-016-0612-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Zhong W, Zhao Y, Sun X, Song Z, McClain CJ, Zhou Z. Dietary zinc deficiency exaggerates ethanol-induced liver injury in mice: involvement of intrahepatic and extrahepatic factors. PLoS One. 2013;8:e76522. [PMID: 24155903 DOI: 10.1371/journal.pone.0076522] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
28 Parente DB, Rodrigues RS, Paiva FF, Oliveira Neto JA, Machado-Silva L, Lanzoni V, Campos CF, Eiras-Araujo AL, do Brasil PE, Garteiser P, Gomes MB, de Mello Perez R. Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One 2014;9:e112574. [PMID: 25426708 DOI: 10.1371/journal.pone.0112574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
29 Kamada Y, Fujii H, Fujii H, Sawai Y, Doi Y, Uozumi N, Mizutani K, Akita M, Sato M, Kida S. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl. 2013;7:648-656. [PMID: 23775887 DOI: 10.1002/prca.201200137] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
30 Minuk GY, Iliant V, Zhou N, Kaita KD, Wong SG, Peretz D, Uhanova J. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. Liver Int 2018;38:1110-6. [DOI: 10.1111/liv.13644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, Sasso FC, Tripodi MF, Persico M. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS One 2017;12:e0178473. [PMID: 28570615 DOI: 10.1371/journal.pone.0178473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
32 Oe Y, Ko M, Fushima T, Sato E, Karumanchi SA, Sato H, Sugawara J, Ito S, Takahashi N. Hepatic dysfunction and thrombocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase. Sci Rep 2018;8:102. [PMID: 29311569 DOI: 10.1038/s41598-017-18260-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
33 Miyoshi E, Kamada Y. Application of glycoscience to the early detection of pancreatic cancer. Cancer Sci 2016;107:1357-62. [PMID: 27418030 DOI: 10.1111/cas.13011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
34 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
35 Zhu YN, Sun YF, He LL, Ren R, Zhang Y, Wang F, Li FH, Zhang YF, Guo PR. Effect of combined prescription and separate prescription of promoting blood circulation and removing blood stasis traditional Chinese medicine on expression of SOCS-3 and SREBP-1c in diabetic fatty liver in rats. Shijie Huaren Xiaohua Zazhi 2013; 21(29): 3089-3096 [DOI: 10.11569/wcjd.v21.i29.3089] [Reference Citation Analysis]
36 Pan SY, Yu Q, Zhang Y, Wang XY, Sun N, Yu ZL, Ko KM. Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity. Lipids Health Dis. 2012;11:120. [PMID: 22989092 DOI: 10.1186/1476-511X-11-120] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
37 Männistö VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, Matte AK, Venesmaa S, Käkelä P, Kärjä V, Arola J, Gylling H, Cederberg H, Kuusisto J, Laakso M, Yki-järvinen H, Ala-korpela M, Pihlajamäki J. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int 2015;35:1853-61. [DOI: 10.1111/liv.12769] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
38 Coulon S, Legry V, Heindryckx F, Van Steenkiste C, Casteleyn C, Olievier K, Libbrecht L, Carmeliet P, Jonckx B, Stassen JM. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology. 2013;57:1793-1805. [PMID: 23299577 DOI: 10.1002/hep.26219] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
39 Morán-Salvador E, López-Parra M, García-Alonso V, Titos E, Martínez-Clemente M, González-Périz A, López-Vicario C, Barak Y, Arroyo V, Clària J. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J 2011;25:2538-50. [PMID: 21507897 DOI: 10.1096/fj.10-173716] [Cited by in Crossref: 251] [Cited by in F6Publishing: 239] [Article Influence: 22.8] [Reference Citation Analysis]
40 Fernando DH, Forbes JM, Angus PW, Herath CB. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. Int J Mol Sci. 2019;20. [PMID: 31614491 DOI: 10.3390/ijms20205037] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
41 Byrne FL, Hoehn KL. Subclassification of fatty liver by its pathogenesis: cIEFing is believing. J Pathol 2016;239:3-5. [PMID: 26880235 DOI: 10.1002/path.4702] [Reference Citation Analysis]
42 Zhang Y, Bobe G, Miranda CL, Lowry MB, Hsu VL, Lohr CV, Wong CP, Jump DB, Robinson MM, Sharpton TJ, Maier CS, Stevens JF, Gombart AF. Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARγ. Elife 2021;10:e66398. [PMID: 34128467 DOI: 10.7554/eLife.66398] [Reference Citation Analysis]
43 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
44 Lückhoff HK, Kruger FC, Kotze MJ. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol 2015; 7(9): 1192-1208 [PMID: 26019735 DOI: 10.4254/wjh.v7.i9.1192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
45 Mancia C, Loustaud-Ratti V, Carrier P, Naudet F, Bellissant E, Labrousse F, Pichon N. Controlled Attenuation Parameter and Liver Stiffness Measurements for Steatosis Assessment in the Liver Transplant of Brain Dead Donors. Transplantation. 2015;99:1619-1624. [PMID: 25719261 DOI: 10.1097/tp.0000000000000652] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
46 Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36-44. [PMID: 27757953 DOI: 10.1002/path.4829] [Cited by in Crossref: 162] [Cited by in F6Publishing: 153] [Article Influence: 27.0] [Reference Citation Analysis]
47 Cahyani DM, Miatmoko A, Hariawan BS, Purwantari KE, Sari R. N-nitrosodiethylamine induces inflammation of liver in mice. J Basic Clin Physiol Pharmacol 2021;32:505-10. [PMID: 34214328 DOI: 10.1515/jbcpp-2020-0475] [Reference Citation Analysis]
48 Goceri E, Shah ZK, Layman R, Jiang X, Gurcan MN. Quantification of liver fat: A comprehensive review. Comput Biol Med 2016;71:174-89. [PMID: 26945465 DOI: 10.1016/j.compbiomed.2016.02.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
49 Bekaert M, Ouwens DM, Hörbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D, Van Nieuwenhove Y, Calders P, Praet M, Hoorens A, Geerts A, Verhelst X, Kaufman J, Lapauw B. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity: Chemerin Expression in Patients with NAFLD. Obesity 2016;24:2544-52. [DOI: 10.1002/oby.21674] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
50 Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, Montemayor S, Mascaró CM, Casares M, Tejada S, Abete I, Zulet MA, Tur JA, Martínez JA, Sureda A. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2020;9:E759. [PMID: 32824349 DOI: 10.3390/antiox9080759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Summa KC, Voigt RM, Forsyth CB, Shaikh M, Cavanaugh K, Tang Y, Vitaterna MH, Song S, Turek FW, Keshavarzian A. Disruption of the Circadian Clock in Mice Increases Intestinal Permeability and Promotes Alcohol-Induced Hepatic Pathology and Inflammation. PLoS One. 2013;8:e67102. [PMID: 23825629 DOI: 10.1371/journal.pone.0067102] [Cited by in Crossref: 134] [Cited by in F6Publishing: 129] [Article Influence: 14.9] [Reference Citation Analysis]
52 De Jesus DF, Orime K, Kaminska D, Kimura T, Basile G, Wang CH, Haertle L, Riemens R, Brown NK, Hu J, Männistö V, Silva AM, Dirice E, Tseng YH, Haaf T, Pihlajamäki J, Kulkarni RN. Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice. J Clin Invest 2020;130:2391-407. [PMID: 32250344 DOI: 10.1172/JCI127502] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
53 Dziodzio T, Biebl M, Öllinger R, Pratschke J, Denecke C. The Role of Bariatric Surgery in Abdominal Organ Transplantation-the Next Big Challenge?Obes Surg. 2017;27:2696-2706. [PMID: 28791580 DOI: 10.1007/s11695-017-2854-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
54 Invernizzi G, Modina S, Corbani D, Bronzo V, Pisani L, Caputo J, Agazzi A, Dell’orto V, Savoini G. Hepatic and subcutaneous adipose tissue variations in transition dairy goats fed saturated or unsaturated fat supplemented diets. Small Ruminant Research 2016;144:211-9. [DOI: 10.1016/j.smallrumres.2016.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Morita S, Neto Dde S, Morita FH, Morita NK, Lobo SM. Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. Obes Surg 2015;25:2335-43. [PMID: 25920616 DOI: 10.1007/s11695-015-1696-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
56 Hellerbrand C, Schattenberg JM, Peterburs P, Lechner A, Brignoli R. The potential of silymarin for the treatment of hepatic disorders. Clin Phytosci 2017;2. [DOI: 10.1186/s40816-016-0019-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Enjoji M, Yasutake K, Kohjima M, Nakamuta M. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol 2012;2012:925807. [PMID: 22550592 DOI: 10.1155/2012/925807] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
58 Tzeng T, Liou S, Liu I. 6-Gingerol mitigates nutritional steatohepatitis through regulating key genes related to oxidative stress, inflammation and fibrogenesis. RSC Adv 2014;4:61427-36. [DOI: 10.1039/c4ra12030b] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300-1306. [PMID: 21750883 DOI: 10.1007/s00535-011-0436-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 6.0] [Reference Citation Analysis]
60 Campos ML, Castro MB, Campos AD, Fernandes MF, Conegundes JLM, Rodrigues MN, Mügge FLB, Silva AMD, Sabarense CM, Castañon MCMN, Andreazzi AE, Scio E. Antiobesity, hepatoprotective and anti-hyperglycemic effects of a pharmaceutical formulation containing Cecropia pachystachya Trécul in mice fed with a hypercaloric diet. J Ethnopharmacol 2021;280:114418. [PMID: 34271111 DOI: 10.1016/j.jep.2021.114418] [Reference Citation Analysis]
61 Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, (JSG-NAFLD) TOJSGON. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(29): 10108-10114 [PMID: 25110437 DOI: 10.3748/wjg.v20.i29.10108] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
62 Parikh P, Ingle M, Patel J, Bhate P, Pandey V, Sawant P. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients. Saudi J Gastroenterol. 2016;22:192-197. [PMID: 27184636 DOI: 10.4103/1319-3767.182451] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
63 Breher-Esch S, Sahini N, Trincone A, Wallstab C, Borlak J. Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease. BMC Med Genomics 2018;11:111. [PMID: 30547786 DOI: 10.1186/s12920-018-0438-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
64 Pereira HA, Dionizio AS, Fernandes MS, Araujo TT, Cestari TM, Buzalaf CP, Iano FG, Buzalaf MA. Fluoride Intensifies Hypercaloric Diet-Induced ER Oxidative Stress and Alters Lipid Metabolism. PLoS One 2016;11:e0158121. [PMID: 27336443 DOI: 10.1371/journal.pone.0158121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
65 Tan CT, Soh NJH, Chang HC, Yu VC. p62/SQSTM1 in liver diseases: the usual suspect with multifarious identities. FEBS J 2021. [PMID: 34882306 DOI: 10.1111/febs.16317] [Reference Citation Analysis]
66 Collin de l'Hortet A, Takeishi K, Guzman-Lepe J, Morita K, Achreja A, Popovic B, Wang Y, Handa K, Mittal A, Meurs N, Zhu Z, Weinberg F, Salomon M, Fox IJ, Deng CX, Nagrath D, Soto-Gutierrez A. Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. Cell Metab 2019;30:385-401.e9. [PMID: 31390551 DOI: 10.1016/j.cmet.2019.06.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
67 Głuszyńska P, Lemancewicz D, Dzięcioł JB, Razak Hady H. Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. J Clin Med 2021;10:5721. [PMID: 34945016 DOI: 10.3390/jcm10245721] [Reference Citation Analysis]
68 Bejaoui M, Zaouali MA, Folch-Puy E, Pantazi E, Bardag-Gorce F, Carbonell T, Oliva J, Rimola A, Abdennebi HB, Roselló-Catafau J. Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways. J Pharm Pharmacol. 2014;66:62-72. [PMID: 24127984 DOI: 10.1111/jphp.12154] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
69 Su RC, Lad A, Breidenbach JD, Blomquist TM, Gunning WT, Dube P, Kleinhenz AL, Malhotra D, Haller ST, Kennedy DJ. Hyperglycemia induces key genetic and phenotypic changes in human liver epithelial HepG2 cells which parallel the Leprdb/J mouse model of non-alcoholic fatty liver disease (NAFLD). PLoS One 2019;14:e0225604. [PMID: 31805072 DOI: 10.1371/journal.pone.0225604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
70 Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815-823. [PMID: 22966992 DOI: 10.1111/apt.12046] [Cited by in Crossref: 119] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
71 Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk. Aliment Pharmacol Ther. 2012;36:345-352. [PMID: 22730920 DOI: 10.1111/j.1365-2036.2012.05196.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
72 Neuman MG, French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PG, Schrum LW, Donohue TM Jr, Kharbanda KK, Cruz M, Opris M. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 2017;102:162-80. [PMID: 28077318 DOI: 10.1016/j.yexmp.2017.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
73 Ostenson J, Damon BM, Welch EB. MR fingerprinting with simultaneous T1, T2, and fat signal fraction estimation with integrated B0 correction reduces bias in water T1 and T2 estimates. Magn Reson Imaging 2019;60:7-19. [PMID: 30910696 DOI: 10.1016/j.mri.2019.03.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
74 Sarna LK, Siow YL, O K. The CBS/CSE system: a potential therapeutic target in NAFLD? Can J Physiol Pharmacol 2015;93:1-11. [PMID: 25493326 DOI: 10.1139/cjpp-2014-0394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
75 Kumagai H, Taniguchi N, Yokoyama K, Katsuyama K, Yamamoto H, Hara S, Hirota N, Itoh K, Yamagata T. The Speed of Sound in Rat Liver With Steatohepatitis: Ex Vivo Analysis Using Two Types of Ultrasound Systems. Ultrasound Med Biol 2019;45:2258-65. [PMID: 31153716 DOI: 10.1016/j.ultrasmedbio.2019.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Parente DB, Oliveira Neto JA, Brasil PEAA, Paiva FF, Ravani JPR, Gomes MB, Lanzoni V, Campos CFF, Machado-silva L, Perez RM, Rodrigues RS. Preperitoneal fat as a non-invasive marker of increased risk of severe non-alcoholic fatty liver disease in patients with type 2 diabetes: Preperitoneal fat and severe fatty liver. Journal of Gastroenterology and Hepatology 2018;33:511-7. [DOI: 10.1111/jgh.13903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
77 Hwang S, Yun H, Moon S, Cho YE, Gao B. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:751802. [PMID: 34707573 DOI: 10.3389/fendo.2021.751802] [Reference Citation Analysis]
78 Luger M, Kruschitz R, Kienbacher C, Traussnigg S, Langer FB, Schindler K, Würger T, Wrba F, Trauner M, Prager G, Ludvik B. Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. Obes Surg 2016;26:2425-32. [PMID: 26989059 DOI: 10.1007/s11695-016-2123-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
79 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013;15:106-15. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
80 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:106-115. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 d'Angelo M, Castelli V, Tupone MG, Catanesi M, Antonosante A, Dominguez-Benot R, Ippoliti R, Cimini AM, Benedetti E. Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs. Int J Mol Sci 2019;20:E5422. [PMID: 31683535 DOI: 10.3390/ijms20215422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Muir AJ. Understanding the Complexities of Cirrhosis. Clinical Therapeutics 2015;37:1822-36. [DOI: 10.1016/j.clinthera.2015.05.507] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
83 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
84 Jüngst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, Lammert F. Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest. 2013;43:1069-1083. [PMID: 23927644 DOI: 10.1111/eci.12128] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
85 Ables GP. Update on pparγ and nonalcoholic Fatty liver disease. PPAR Res 2012;2012:912351. [PMID: 22966224 DOI: 10.1155/2012/912351] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
86 Oses M, Medrano M, Galbete A, Arenaza L, Ruiz JR, Sánchez-Valverde F, Ortega FB, Labayen I. A sociodemographic, anthropometric and lifestyle-based prediction score for screening children with overweight and obesity for hepatic steatosis: The HEPAKID index. Pediatr Obes 2021;16:e12770. [PMID: 33403830 DOI: 10.1111/ijpo.12770] [Reference Citation Analysis]
87 Leitão HS, Doblas S, d'Assignies G, Garteiser P, Daire JL, Paradis V, Geraldes CF, Vilgrain V, Van Beers BE. Fat deposition decreases diffusion parameters at MRI: a study in phantoms and patients with liver steatosis. Eur Radiol 2013;23:461-7. [PMID: 22935901 DOI: 10.1007/s00330-012-2626-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
88 Teresa Borrello M, Rita Emma M, Listi A, Rubis M, Coslet S, Augello G, Cusimano A, Cabibi D, Porcasi R, Giannitrapani L, Soresi M, Pantuso G, Blyth K, Montalto G, Pin C, Cervello M, Iovanna J. NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response. FASEB J 2021;35:e21395. [PMID: 33566371 DOI: 10.1096/fj.202002413RR] [Reference Citation Analysis]
89 d'Assignies G, Fayard C, Leitao H, Alfaiate T, Tubach F, Dokmak S, Paradis V, Van Beers BE, Ronot M, Vilgrain V. Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection. Surgery 2016;159:1050-7. [DOI: 10.1016/j.surg.2015.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
90 Lal A, Parai JL, Milroy CM. Liver Pathology in First Presentation Diabetic Ketoacidosis at Autopsy. Acad Forensic Pathol 2016;6:271-80. [PMID: 31239898 DOI: 10.23907/2016.028] [Reference Citation Analysis]
91 Sahebkar A, Sancho E, Abelló D, Camps J, Joven J. Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review. J Cell Physiol 2018;233:849-55. [PMID: 28063221 DOI: 10.1002/jcp.25779] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
92 Saberi B, Dadabhai AS, Jang YY, Gurakar A, Mezey E. Current Management of Alcoholic Hepatitis and Future Therapies. J Clin Transl Hepatol 2016;4:113-22. [PMID: 27350941 DOI: 10.14218/JCTH.2016.00006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
93 van der Graaff D, Kwanten WJ, Francque SM. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Med Hypotheses 2019;122:188-97. [PMID: 30593409 DOI: 10.1016/j.mehy.2018.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
94 Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22:1044-1049. [PMID: 22108808 DOI: 10.1007/s11695-011-0559-y] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
95 Benhammou JN, Ko A, Alvarez M, Kaikkonen MU, Rankin C, Garske KM, Padua D, Bhagat Y, Kaminska D, Kärjä V, Pihlajamäki J, Pisegna JR, Pajukanta P. Novel Lipid Long Intervening Noncoding RNA, Oligodendrocyte Maturation-Associated Long Intergenic Noncoding RNA, Regulates the Liver Steatosis Gene Stearoyl-Coenzyme A Desaturase As an Enhancer RNA.Hepatol Commun. 2019;3:1356-1372. [PMID: 31592021 DOI: 10.1002/hep4.1413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
96 Hassan NF, Soliman GM, Okasha EF, Shalaby AM. Histological, Immunohistochemical, and Biochemical Study of Experimentally Induced Fatty Liver in Adult Male Albino Rat and the Possible Protective Role of Pomegranate. J Microsc Ultrastruct 2018;6:44-55. [PMID: 30023266 DOI: 10.4103/JMAU.JMAU_5_18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
97 Sid V, Siow YL, O K. Role of folate in nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2017;95:1141-1148. [PMID: 28460180 DOI: 10.1139/cjpp-2016-0681] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
98 Melnyk S, Korourian S, Levy JW, Pavliv O, Evans T, Hakkak R. Effects of Obesity on Pro-Oxidative Conditions and DNA Damage in Liver of DMBA-Induced Mammary Carcinogenesis Models. Metabolites 2017;7:E26. [PMID: 28594380 DOI: 10.3390/metabo7020026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
99 Gaia S, Campion D, Evangelista A, Spandre M, Cosso L, Brunello F, Ciccone G, Bugianesi E, Rizzetto M. Non-invasive score system for fibrosis in chronic hepatitis: proposal for a model based on biochemical, FibroScan and ultrasound data. Liver Int 2015;35:2027-35. [PMID: 25495478 DOI: 10.1111/liv.12761] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
100 Cho CS, Park HW, Ho A, Semple IA, Kim B, Jang I, Park H, Reilly S, Saltiel AR, Lee JH. Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 2018;68:1331-46. [PMID: 29251796 DOI: 10.1002/hep.29742] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
101 Sinton MC, Hay DC, Drake AJ. Metabolic control of gene transcription in non-alcoholic fatty liver disease: the role of the epigenome. Clin Epigenetics 2019;11:104. [PMID: 31319896 DOI: 10.1186/s13148-019-0702-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
102 Venturi C, Sempoux C, Bueno J, Ferreres Pinas JC, Bourdeaux C, Abarca-Quinones J, Rahier J, Reding R. Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children. Am J Transplant. 2012;12:2986-2996. [PMID: 22882699 DOI: 10.1111/j.1600-6143.2012.04210.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
103 Kakar S, Dugum M, Cabello R, Humar A, Ahmad J, Malik SM. Incidence of Recurrent NASH-Related Allograft Cirrhosis. Dig Dis Sci 2019;64:1356-63. [PMID: 30560336 DOI: 10.1007/s10620-018-5413-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
104 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
105 Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9:152-61. [DOI: 10.1038/nrgastro.2011.273] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
106 Barbois S, Arvieux C, Leroy V, Reche F, Stürm N, Borel A. Benefit–risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. Surgery for Obesity and Related Diseases 2017;13:1780-6. [DOI: 10.1016/j.soard.2017.07.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
107 Kapravelou G, Martínez R, Andrade AM, Nebot E, Camiletti-Moirón D, Aparicio VA, Lopez-Jurado M, Aranda P, Arrebola F, Fernandez-Segura E, Bermano G, Goua M, Galisteo M, Porres JM. Aerobic interval exercise improves parameters of nonalcoholic fatty liver disease (NAFLD) and other alterations of metabolic syndrome in obese Zucker rats. Appl Physiol Nutr Metab 2015;40:1242-52. [PMID: 26509584 DOI: 10.1139/apnm-2015-0141] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
108 Di Pasqua LG, Cagna M, Berardo C, Vairetti M, Ferrigno A. Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. Biomedicines 2022;10:194. [DOI: 10.3390/biomedicines10010194] [Reference Citation Analysis]
109 Stokes CS, Lammert F, Krawczyk M. Short-term Dietary Interventions for the Management of Nonalcoholic Fatty Liver. Curr Med Chem 2019;26:3483-96. [PMID: 28482789 DOI: 10.2174/0929867324666170508144409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
110 van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of Non-Alcoholic Fatty Liver Disease in HIV-infected patients: The next big thing? Infect Dis Ther. 2019;8:33-50. [PMID: 30607807 DOI: 10.1007/s40121-018-0229-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
111 Elhosary MA, Bahey-el-din M, Abdelbary A, El Guink N, Aboushleib HM. Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model. Microbial Pathogenesis 2019;131:181-5. [DOI: 10.1016/j.micpath.2019.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
112 García-Monzón C, Vargas-Castrillón J, Porrero JL, Alonso MT, Bonachía O, Castillo MJ, Marcos A, Quirós E, Ramos B, Sánchez-Cabezudo C, Villar S, Sáez A, Rodríguez de Cía J, del Pozo E, Vega-Piris L, Soto-Fernández S, Lo Iacono O, Miquilena-Colina ME. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. Liver Int 2015;35:1983-91. [PMID: 25708133 DOI: 10.1111/liv.12813] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
113 Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol 2015; 7(11): 1450-1459 [PMID: 26085906 DOI: 10.4254/wjh.v7.i11.1450] [Cited by in Crossref: 116] [Cited by in F6Publishing: 98] [Article Influence: 16.6] [Reference Citation Analysis]
114 Pataky Z, Genton L, Spahr L, Lazarevic V, Terraz S, Gaïa N, Rubbia-brandt L, Golay A, Schrenzel J, Pichard C. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 2016;61:2721-31. [DOI: 10.1007/s10620-016-4179-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
115 Jwa H, Choi Y, Park UH, Um SJ, Yoon SK, Park T. Piperine, an LXRα antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet. Biochem Pharmacol. 2012;84:1501-1510. [PMID: 23000915 DOI: 10.1016/j.bcp.2012.09.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
116 Wang J, Li P, Jiang Z, Yang Q, Mi Y, Liu Y, Shi R, Zhou Y, Wang J, Lu W, Li S, Liu D. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD. Korean J Intern Med 2016;31:479-87. [PMID: 27025268 DOI: 10.3904/kjim.2015.253] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
117 Giannetti M, Piaggi P, Ceccarini G, Mazzeo S, Querci G, Fierabracci P, Salvetti G, Galli G, Ricco I, Martinelli S, Di Salvo C, Anselmino M, Landi A, Vitti P, Pinchera A, Santini F. Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding. Int J Obes (Lond). 2012;36:336-341. [PMID: 22143620 DOI: 10.1038/ijo.2011.243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
118 Parikh P, Patel J, Ingle M, Sawant P. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India. Indian J Gastroenterol. 2015;34:200-208. [PMID: 26108652 DOI: 10.1007/s12664-015-0572-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
119 Shubham K, Vinay L, Vinod PK. Systems-level organization of non-alcoholic fatty liver disease progression network. Mol Biosyst 2017;13:1898-911. [PMID: 28745372 DOI: 10.1039/c7mb00013h] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
120 Cerović I, Mladenović D, Ješić R, Naumović T, Branković M, Vučević D, Aleksić V, Radosavljević T. Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013;25:899-904. [PMID: 23426271 DOI: 10.1097/MEG.0b013e32835f0786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
121 Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology. 2015;62:1433-1443. [PMID: 26199205 DOI: 10.1002/hep.28002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
122 Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Abdelmalek M, Doo E, Tonascia JA, Kleiner DE, Sanyal AJ, Chalasani N; NASH Clinical Research Network. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67:134-44. [PMID: 28859228 DOI: 10.1002/hep.29489] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 20.0] [Reference Citation Analysis]
123 Dai FJ, Hsu WH, Huang JJ, Wu SC. Effect of pigeon pea (Cajanus cajan L.) on high-fat diet-induced hypercholesterolemia in hamsters. Food Chem Toxicol 2013;53:384-91. [PMID: 23287313 DOI: 10.1016/j.fct.2012.12.029] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
124 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
125 Zhang X, Gao X, Zhang P, Guo Y, Lin H, Diao X, Liu Y, Dong C, Hu Y, Chen S, Chen X. Dynamic mechanical analysis to assess viscoelasticity of liver tissue in a rat model of nonalcoholic fatty liver disease. Med Eng Phys 2017;44:79-86. [PMID: 28284571 DOI: 10.1016/j.medengphy.2017.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
126 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013.34] [Cited by in Crossref: 278] [Cited by in F6Publishing: 267] [Article Influence: 30.9] [Reference Citation Analysis]
127 Catta-Preta M, Mendonca LS, Fraulob-Aquino J, Aguila MB, Mandarim-de-Lacerda CA. A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. Virchows Arch. 2011;459:477-485. [PMID: 21901430 DOI: 10.1007/s00428-011-1147-1] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 7.1] [Reference Citation Analysis]
128 Urasaki Y, Fiscus RR, Le TT. Molecular classification of fatty liver by high-throughput profiling of protein post-translational modifications: Molecular classification of fatty liver. J Pathol 2016;238:641-50. [DOI: 10.1002/path.4685] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
129 Kumagai H, Yokoyama K, Katsuyama K, Hara S, Yamamoto H, Yamagata T, Taniguchi N, Hirota N, Itoh K. A New Method for Measuring the Speed of Sound in Rat Liver ex Vivo Using an Ultrasound System: Correlation of Sound Speed with Fat Deposition. Ultrasound in Medicine & Biology 2014;40:2499-507. [DOI: 10.1016/j.ultrasmedbio.2014.03.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
130 Imbault M, Faccinetto A, Osmanski BF, Tissier A, Deffieux T, Gennisson JL, Vilgrain V, Tanter M. Robust sound speed estimation for ultrasound-based hepatic steatosis assessment. Phys Med Biol. 2017;62:3582-3598. [PMID: 28225357 DOI: 10.1088/1361-6560/aa6226] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 10.8] [Reference Citation Analysis]
131 Alisi A, Carpino G, Nobili V. Paediatric nonalcoholic fatty liver disease: . Current Opinion in Gastroenterology 2013;29:279-84. [DOI: 10.1097/mog.0b013e32835ff95e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
132 Rogier J, Roullet S, Cornélis F, Biais M, Quinart A, Revel P, Bioulac-Sage P, Le Bail B. Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio. Liver Transpl 2015;21:690-5. [PMID: 25761371 DOI: 10.1002/lt.24105] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
133 Bratoeva K, Nikolova S, Merdzhanova A, Stoyanov GS, Dimitrova E, Kashlov J, Conev N, Radanova M. Association Between Serum CK-18 Levels and the Degree of Liver Damage in Fructose-Induced Metabolic Syndrome. Metab Syndr Relat Disord 2018;16:350-7. [PMID: 29989845 DOI: 10.1089/met.2017.0162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
134 Lefebvre T, Petitclerc L, Hébert M, Bilodeau L, Sebastiani G, Olivié D, Gao ZH, Sylvestre MP, Cloutier G, Nguyen BN, Gilbert G, Tang A. MRI cine-tagging of cardiac-induced motion for noninvasive staging of liver fibrosis. J Magn Reson Imaging 2020;51:1570-80. [PMID: 31605412 DOI: 10.1002/jmri.26935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Yan J, Yu Y, Kang JW, Tam ZY, Xu S, Fong ELS, Singh SP, Song Z, Tucker-Kellogg L, So PTC, Yu H. Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy. J Biophotonics 2017;10:1703-13. [PMID: 28635128 DOI: 10.1002/jbio.201600303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
136 Orona NS, Astort F, Maglione GA, Ferraro SA, Martin M, Morales C, Mandalunis PM, Brites F, Tasat DR. Hazardous effects of urban air particulate matter acute exposure on lung and extrapulmonary organs in mice. Ecotoxicology and Environmental Safety 2020;190:110120. [DOI: 10.1016/j.ecoenv.2019.110120] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
137 Arindkar S, Bhattacharjee J, Kumar JM, Das B, Upadhyay P, Asif S, Juyal RC, Majumdar SS, Perumal N. Antigen peptide transporter 1 is involved in the development of fructose-induced hepatic steatosis in mice. J Gastroenterol Hepatol. 2013;28:1403-1409. [PMID: 23488792 DOI: 10.1111/jgh.12186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
138 Kamada Y, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, Doi Y, Asazawa H, Nakayama K, Mizutani K. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One. 2013;8:e66328. [PMID: 23805214 DOI: 10.1371/journal.pone.0066328] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
139 Xia Y, Li Q, Zhong W, Dong J, Wang Z, Wang C. L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndr 2011;3:31. [PMID: 22082204 DOI: 10.1186/1758-5996-3-31] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
140 Schwertheim S, Kälsch J, Jastrow H, Schaefer CM, Theurer S, Ting S, Canbay A, Wedemeyer H, Schmid KW, Baba HA. Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. Sci Rep 2020;10:16533. [PMID: 33024131 DOI: 10.1038/s41598-020-71646-y] [Reference Citation Analysis]
141 Jain AK, le Roux CW, Puri P, Tavakkoli A, Gletsu-Miller N, Laferrère B, Kellermayer R, DiBaise JK, Martindale RG, Wolfe BM. Proceedings of the 2017 ASPEN Research Workshop-Gastric Bypass: Role of the Gut. JPEN J Parenter Enteral Nutr 2018;42:279-95. [PMID: 29443403 DOI: 10.1002/jpen.1121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
142 Leitão HS, Paulino C, Rodrigues D, Gonçalves SI, Marques C, Carvalheiro M, Geraldes CF, Caseiro-alves F. MR Fat Fraction Mapping. Academic Radiology 2013;20:957-61. [DOI: 10.1016/j.acra.2013.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
143 Vazquez-Chantada M, Gonzalez-Lahera A, Martinez-Arranz I, Garcia-Monzon C, Regueiro MM, Garcia-Rodriguez JL, Schlangen KA, Mendibil I, Rodriguez-Ezpeleta N, Lozano JJ. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. Hepatology. 2013;57:505-514. [PMID: 22961556 DOI: 10.1002/hep.26052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
144 Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 2014;5:189-200. [DOI: 10.1586/egh.11.21] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
145 Tan Y, Lao W, Xiao L, Wang Z, Xiao W, Kamal MA, Seale JP, Qu X. Managing the combination of nonalcoholic Fatty liver disease and metabolic syndrome with chinese herbal extracts in high-fat-diet fed rats. Evid Based Complement Alternat Med 2013;2013:306738. [PMID: 23476686 DOI: 10.1155/2013/306738] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
146 Maeda T, Miki S, Morihara N, Kagawa Y. Aged garlic extract ameliorates fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance. Exp Ther Med 2019;18:857-66. [PMID: 31281460 DOI: 10.3892/etm.2019.7636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
147 Li X, Guo X, Ji H, Yu G, Gao P. Gallstones in Patients with Chronic Liver Diseases. Biomed Res Int 2017;2017:9749802. [PMID: 28251162 DOI: 10.1155/2017/9749802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
148 Parente DB, Perazzo H, Paiva FF, Campos CFF, Saboya CJ, Pereira SE, Silva FDE, Rodrigues RS, Perez RM. Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study. Sci Rep 2020;10:15007. [PMID: 32929103 DOI: 10.1038/s41598-020-71723-2] [Reference Citation Analysis]
149 Manzanilla Valdez ML, Segura Campos MR. Renal and Hepatic Disease: Cnidoscolus aconitifolius as Diet Therapy Proposal for Prevention and Treatment. J Am Coll Nutr 2021;40:646-64. [PMID: 33301380 DOI: 10.1080/07315724.2020.1810171] [Reference Citation Analysis]
150 Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington NJ. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2013;41:554-561. [PMID: 23223517 DOI: 10.1124/dmd.112.048439] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
151 Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr. 2014;173:131-139. [PMID: 24068459 DOI: 10.1007/s00431-013-2157-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
152 Teng B, Huang C, Cheng CL, Udduttula A, Yu XF, Liu C, Li J, Yao ZY, Long J, Miao LF, Zou C, Chu J, Zhang JV, Ren PG. Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A. J Hepatol. 2020;73:383-393. [PMID: 32147363 DOI: 10.1016/j.jhep.2020.02.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
153 Mann JP, De Vito R, Mosca A, Alisi A, Armstrong MJ, Raponi M, Baumann U, Nobili V. Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. Hepatology. 2016;63:745-753. [PMID: 26638195 DOI: 10.1002/hep.28374] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
154 Khairalseed M, Brown K, Parker KJ, Hoyt K. Real-time H-scan ultrasound imaging using a Verasonics research scanner. Ultrasonics 2019;94:28-36. [PMID: 30606648 DOI: 10.1016/j.ultras.2018.12.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
155 Yilmaz Y. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome? World J Hepatol 2012; 4(12): 332-334 [PMID: 23355910 DOI: 10.4254/wjh.v4.i12.332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
156 Ding L, Liu JL, Hassan W, Wang LL, Yan FR, Shang J. Lipid modulatory activities of Cichorium glandulosum Boiss et Huet are mediated by multiple components within hepatocytes. Sci Rep 2014;4:4715. [PMID: 24797163 DOI: 10.1038/srep04715] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
157 Parente DB, Paiva FF, Oliveira Neto JA, Machado-Silva L, Figueiredo FA, Lanzoni V, Campos CF, do Brasil PE, Gomes Mde B, Perez Rde M, Rodrigues RS. Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients. PLoS One 2015;10:e0125653. [PMID: 25961735 DOI: 10.1371/journal.pone.0125653] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
158 Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014;25:473-86. [PMID: 24802098 DOI: 10.1007/s00335-014-9521-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
159 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
160 Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015;7:1450-1459. [PMID: 26085906 DOI: 10.4254/wjh.v7.i11] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes 2019;12:1001-12. [PMID: 31308716 DOI: 10.2147/DMSO.S212715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
162 Szary N, Rector RS, Uptergrove GM, Ridenhour SE, Shukla SD, Thyfault JP, Koch LG, Britton SL, Ibdah JA. High Intrinsic Aerobic Capacity Protects against Ethanol-Induced Hepatic Injury and Metabolic Dysfunction: Study Using High Capacity Runner Rat Model. Biomolecules 2015;5:3295-308. [PMID: 26610588 DOI: 10.3390/biom5043295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
163 Lotowska JM, Sobaniec-Lotowska ME, Bockowska SB, Lebensztejn DM. Pediatric non-alcoholic steatohepatitis: The first report on the ultrastructure of hepatocyte mitochondria. World J Gastroenterol 2014; 20(15): 4335-4340 [PMID: 24764670 DOI: 10.3748/wjg.v20.i15.4335] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
164 Eren F, Kurt R, Ermis F, Atug O, Imeryuz N, Yilmaz Y. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem. 2012;45:655-658. [PMID: 22465275 DOI: 10.1016/j.clinbiochem.2012.03.019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
165 Lund MT, Kristensen M, Hansen M, Tveskov L, Floyd AK, Støckel M, Vainer B, Poulsen SS, Helge JW, Prats C, Dela F. Hepatic mitochondrial oxidative phosphorylation is normal in obese patients with and without type 2 diabetes. J Physiol 2016;594:4351-8. [PMID: 27060482 DOI: 10.1113/JP272105] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
166 Flisiak-Jackiewicz M, Bobrus-Chociej A, Tarasów E, Wojtkowska M, Białokoz-Kalinowska I, Lebensztejn DM. Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children. Can J Gastroenterol Hepatol 2018;2018:3870454. [PMID: 29854715 DOI: 10.1155/2018/3870454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
167 Chu MJ, Hickey AJ, Phillips AR, Bartlett AS. The impact of hepatic steatosis on hepatic ischemia-reperfusion injury in experimental studies: a systematic review. Biomed Res Int. 2013;2013:192029. [PMID: 24062999 DOI: 10.1155/2013/192029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
168 Amorim VB, Parente DB, Paiva FF, Oliveira Neto JA, Miranda AA, Moreira CC, Fernandes FF, Campos CFF, Leite NC, Perez RM, Rodrigues RS. Can gadoxetic acid–enhanced magnetic resonance imaging be used to avoid liver biopsy in patients with nonalcoholic fatty liver disease? World J Hepatol 2020; 12(9): 661-671 [PMID: 33033571 DOI: 10.4254/wjh.v12.i9.661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol 2019;13:447-61. [PMID: 30875479 DOI: 10.1080/17474124.2019.1595589] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
170 McDyre BC, AbdulHameed MDM, Permenter MG, Dennis WE, Baer CE, Koontz JM, Boyle MH, Wallqvist A, Lewis JA, Ippolito DL. Comparative Proteomic Analysis of Liver Steatosis and Fibrosis after Oral Hepatotoxicant Administration in Sprague-Dawley Rats. Toxicol Pathol 2018;46:202-23. [PMID: 29378501 DOI: 10.1177/0192623317747549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
171 Kim KY, Song JS, Kannengiesser S, Han YM. Hepatic fat quantification using the proton density fat fraction (PDFF): utility of free-drawn-PDFF with a large coverage area. Radiol Med 2015;120:1083-93. [PMID: 25952293 DOI: 10.1007/s11547-015-0545-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
172 Souza MRDA, Diniz MDFFDM, Medeiros-filho JEMD, Araújo MSTD. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012;49:89-96. [DOI: 10.1590/s0004-28032012000100015] [Cited by in Crossref: 102] [Cited by in F6Publishing: 72] [Article Influence: 10.2] [Reference Citation Analysis]
173 Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol 2014; 6(8): 570-579 [PMID: 25232450 DOI: 10.4254/wjh.v6.i8.570] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 7.9] [Reference Citation Analysis]
174 Piotrowska K, Borkowska SJ, Wiszniewska B, Laszczyńska M, Słuczanowska-Głabowska S, Havens AM, Kopchick JJ, Bartke A, Taichman RS, Kucia M, Ratajczak MZ. The effect of low and high plasma levels of insulin-like growth factor-1 (IGF-1) on the morphology of major organs: studies of Laron dwarf and bovine growth hormone transgenic (bGHTg) mice. Histol Histopathol 2013;28:1325-36. [PMID: 23613169 DOI: 10.14670/HH-28.1325] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
175 Tang Y, Zhang L, Forsyth CB, Shaikh M, Song S, Keshavarzian A. The Role of miR-212 and iNOS in Alcohol-Induced Intestinal Barrier Dysfunction and Steatohepatitis. Alcohol Clin Exp Res 2015;39:1632-41. [PMID: 26207424 DOI: 10.1111/acer.12813] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
176 Feng S, Lai JC. Expanded criteria donors. Clin Liver Dis 2014;18:633-49. [PMID: 25017080 DOI: 10.1016/j.cld.2014.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
177 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013. 34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, Wong DK, Lai CL, Yuen MF. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. J Viral Hepat. 2018;25:97-104. [PMID: 28772340 DOI: 10.1111/jvh.12766] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
179 Lee YJ, Jang YN, Han YM, Kim HM, Jeong JM, Son MJ, Jin CB, Kim HJ, Seo HS. Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARδ and Adiponectin in ApoE KO Mice. PPAR Res 2017;2017:3912567. [PMID: 29201040 DOI: 10.1155/2017/3912567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
180 Chu MJ, Phillips AR, Hosking AW, MacDonald JR, Bartlett AS, Hickey AJ. Hepatic mitochondrial function analysis using needle liver biopsy samples. PLoS One 2013;8:e79097. [PMID: 24205366 DOI: 10.1371/journal.pone.0079097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
181 Weisell J, Ruotsalainen AK, Näpänkangas J, Jauhiainen M, Rysä J. Menaquinone 4 increases plasma lipid levels in hypercholesterolemic mice. Sci Rep 2021;11:3014. [PMID: 33542347 DOI: 10.1038/s41598-021-82724-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Reis-Júnior P, Tanigawa R, de Mesquita GHA, Basan N, Alves V, D'Albuquerque LAC, Andraus W. Steatosis and steatohepatitis found in adults after death due to non-burn trauma. Clinics (Sao Paulo) 2019;74:e1070. [PMID: 31618320 DOI: 10.6061/clinics/2019/e1070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 Lau JKC, Zhang X, Yu J. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 139-47. [DOI: 10.1007/978-981-10-8684-7_11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
184 Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ; American Association for the Study of Liver Diseases NASH Task Force. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 2021;73:2028-38. [PMID: 33111374 DOI: 10.1002/hep.31599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
185 Orlacchio A, Bolacchi F, Antonicoli M, Coco I, Costanzo E, Tosti D, Francioso S, Angelico M, Simonetti G. Liver elasticity in NASH patients evaluated with real-time elastography (RTE). Ultrasound Med Biol. 2012;38:537-544. [PMID: 22341049 DOI: 10.1016/j.ultrasmedbio.2011.12.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
186 Dionizio A, Pereira HABS, Araujo TT, Sabino-arias IT, Fernandes MS, Oliveira KA, Raymundo FS, Cestari TM, Nogueira FN, Carvalho RA, Buzalaf MAR. Effect of Duration of Exposure to Fluoride and Type of Diet on Lipid Parameters and De Novo Lipogenesis. Biol Trace Elem Res 2019;190:157-71. [DOI: 10.1007/s12011-018-1542-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016;17:68-80. [PMID: 26597657 DOI: 10.1111/obr.12333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
188 Velasco-Chong JR, Herrera-Calderón O, Rojas-Armas JP, Hañari-Quispe RD, Figueroa-Salvador L, Peña-Rojas G, Andía-Ayme V, Yuli-Posadas RÁ, Yepes-Perez AF, Aguilar C. TOCOSH FLOUR (Solanum tuberosum L.): A Toxicological Assessment of Traditional Peruvian Fermented Potatoes. Foods 2020;9:E719. [PMID: 32498434 DOI: 10.3390/foods9060719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Savari F, Mard SA, Badavi M, Rezaie A, Gharib-Naseri MK. A new method to induce nonalcoholic steatohepatitis (NASH) in mice. BMC Gastroenterol 2019;19:125. [PMID: 31307427 DOI: 10.1186/s12876-019-1041-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
190 McGettigan B, McMahan R, Orlicky D, Burchill M, Danhorn T, Francis P, Cheng LL, Golden-Mason L, Jakubzick CV, Rosen HR. Dietary Lipids Differentially Shape Nonalcoholic Steatohepatitis Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages. Hepatology. 2019;70:67-83. [PMID: 30516830 DOI: 10.1002/hep.30401] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
191 Amin NB, Carvajal-Gonzalez S, Purkal J, Zhu T, Crowley C, Perez S, Chidsey K, Kim AM, Goodwin B. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019;11. [PMID: 31776293 DOI: 10.1126/scitranslmed.aav9701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
192 Della Corte C, Mosca A, Vania A, Alterio A, Iasevoli S, Nobili V. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study. Nutrition. 2017;39-40:8-14. [PMID: 28606575 DOI: 10.1016/j.nut.2017.02.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 9.6] [Reference Citation Analysis]
193 Foster SR, Dilworth LL, Thompson RK, Alexander-lindo RL, Omoruyi FO. Effects of combined inositol hexakisphosphate and inositol supplement on antioxidant activity and metabolic enzymes in the liver of streptozotocin-induced type 2 diabetic rats. Chemico-Biological Interactions 2017;275:108-15. [DOI: 10.1016/j.cbi.2017.07.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
194 Róvero Costa M, Leite Garcia J, Cristina Vágula de Almeida Silva C, Junio Togneri Ferron A, Valentini Francisqueti-Ferron F, Kurokawa Hasimoto F, Schmitt Gregolin C, Henrique Salomé de Campos D, Roberto de Andrade C, Dos Anjos Ferreira AL, Renata Corrêa C, Moreto F. Lycopene Modulates Pathophysiological Processes of Non-Alcoholic Fatty Liver Disease in Obese Rats. Antioxidants (Basel) 2019;8:E276. [PMID: 31387231 DOI: 10.3390/antiox8080276] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
195 Reichman TW, Therapondos G, Serrano MS, Seal J, Evers-Meltzer R, Bohorquez H, Cohen A, Carmody I, Ahmed E, Bruce D, Loss GE. “Weighing the risk”: Obesity and outcomes following liver transplantation. World J Hepatol 2015; 7(11): 1484-1493 [PMID: 26085908 DOI: 10.4254/wjh.v7.i11.1484] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
196 Parmar N, Atiq M, Austin L, Miller RA, Smyrk T, Ahmed K. Glycogenic Hepatopathy: Thinking Outside the Box. Case Rep Gastroenterol. 2015;9:221-226. [PMID: 26269698 DOI: 10.1159/000437048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
197 Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(42): 15539-15548 [PMID: 25400438 DOI: 10.3748/wjg.v20.i42.15539] [Cited by in CrossRef: 165] [Cited by in F6Publishing: 140] [Article Influence: 20.6] [Reference Citation Analysis]
198 Lédinghen V, Vergniol J, Foucher J, Merrouche W, Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-8. [DOI: 10.1111/j.1478-3231.2012.02820.x] [Cited by in Crossref: 206] [Cited by in F6Publishing: 189] [Article Influence: 20.6] [Reference Citation Analysis]
199 Yousef MH, Al Juboori A, Albarrak AA, Ibdah JA, Tahan V. Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients. World J Gastrointest Pathophysiol 2017; 8(3): 100-107 [PMID: 28868179 DOI: 10.4291/wjgp.v8.i3.100] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
200 Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102:84-95. [PMID: 23545492 DOI: 10.1016/j.ygeno.2013.03.007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
201 Peleg N, Issachar A, Sneh-Arbib O, Shlomai A. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. Dig Liver Dis. 2017;49:1133-1138. [PMID: 28572039 DOI: 10.1016/j.dld.2017.05.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
202 Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012;51:305-312. [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
203 Papatheodoridi M, Hiriart JB, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, Marra F, Thiele M, Markakis G, Payance A, Brodkin E, Castera L, Papatheodoridis G, Krag A, Arena U, Mueller S, Cales P, Calvaruso V, de Ledinghen V, Pinzani M, Tsochatzis EA. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol 2021;74:1109-16. [PMID: 33307138 DOI: 10.1016/j.jhep.2020.11.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
204 de Souza DA, Parente DB, de Araújo AL, Mortelé KJ. Modern imaging evaluation of the liver: emerging MR imaging techniques and indications. Magn Reson Imaging Clin N Am 2013;21:337-63. [PMID: 23642557 DOI: 10.1016/j.mric.2013.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
205 Vesković M, Labudović-borović M, Zaletel I, Rakočević J, Mladenović D, Jorgačević B, Vučević D, Radosavljević T. The Effects of Betaine on the Nuclear Fractal Dimension, Chromatin Texture, and Proliferative Activity in Hepatocytes in Mouse Model of Nonalcoholic Fatty Liver Disease. Microsc Microanal 2018;24:132-8. [DOI: 10.1017/s1431927617012806] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
206 García-monzón C, Lo Iacono O, Crespo J, Romero-gómez M, García-samaniego J, Fernández-bermejo M, Domínguez-díez A, Rodríguez de Cía J, Sáez A, Porrero JL, Vargas-castrillón J, Chávez-jiménez E, Soto-fernández S, Díaz A, Gallego-durán R, Madejón A, Miquilena-colina ME. Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. Eur J Clin Invest 2014;44:65-73. [DOI: 10.1111/eci.12192] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
207 Jayakumar S, Harrison SA, Loomba R. Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep 2016;15:86-95. [PMID: 27795938 DOI: 10.1007/s11901-016-0296-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
208 Loyer X, Paradis V, Hénique C, Vion AC, Colnot N, Guerin CL, Devue C, On S, Scetbun J, Romain M, Paul JL, Rothenberg ME, Marcellin P, Durand F, Bedossa P, Prip-Buus C, Baugé E, Staels B, Boulanger CM, Tedgui A, Rautou PE. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut 2016;65:1882-94. [PMID: 26338827 DOI: 10.1136/gutjnl-2014-308883] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 10.7] [Reference Citation Analysis]
209 Doulberis M, Polyzos SA, Papaefthymiou A, Katsinelos P, Kiosses C, Kountouras J. Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. Expert Opin Pharmacother 2020;21:247-51. [PMID: 31893958 DOI: 10.1080/14656566.2019.1702967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
210 Kramer JA, Grindley J, Crowell AM, Makaron L, Kohli R, Kirby M, Mansfield KG, Wachtman LM. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Vet Pathol 2015;52:404-13. [PMID: 24913270 DOI: 10.1177/0300985814537839] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
211 Awad AS, Abd Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol 2016;389:381-91. [PMID: 26753695 DOI: 10.1007/s00210-015-1207-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
212 Petäjä E, Yki-järvinen H. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review. IJMS 2016;17:633. [DOI: 10.3390/ijms17050633] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 12.5] [Reference Citation Analysis]
213 Sodhi K, Bracero L, Feyh A, Nichols A, Srikanthan K, Latif T, Preston D, Shapiro JI, Elitsur Y. Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children. J Clin Cell Immunol 2016;7:393. [PMID: 27182456 DOI: 10.4172/2155-9899.1000393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
214 Chu MJ, Vather R, Hickey AJ, Phillips AR, Bartlett AS. Impact of ischaemic preconditioning on experimental steatotic livers following hepatic ischaemia-reperfusion injury: a systematic review. HPB (Oxford). 2015;17:1-10. [PMID: 24712641 DOI: 10.1111/hpb.12258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]